| __timestamp | Amicus Therapeutics, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 51796000 |
| Thursday, January 1, 2015 | 76943000 | 72758000 |
| Friday, January 1, 2016 | 104793000 | 61008000 |
| Sunday, January 1, 2017 | 149310000 | 66962000 |
| Monday, January 1, 2018 | 270902000 | 84888000 |
| Tuesday, January 1, 2019 | 286378000 | 107068000 |
| Wednesday, January 1, 2020 | 308443000 | 122964000 |
| Friday, January 1, 2021 | 272049000 | 208808000 |
| Saturday, January 1, 2022 | 276677000 | 253297000 |
| Sunday, January 1, 2023 | 152381000 | 216566000 |
Unleashing the power of data
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Amicus consistently increased its R&D spending, peaking in 2020 with a 547% increase from 2014. However, a notable decline occurred in 2023, with a 50% drop from its 2020 peak. In contrast, BioCryst's R&D expenses surged by 318% from 2014 to 2023, with a significant leap in 2022, marking a 107% increase from 2020. This divergence highlights Amicus's early aggressive investment strategy, while BioCryst's recent surge suggests a strategic pivot towards innovation. As these companies navigate the evolving biotech landscape, their R&D spending patterns offer valuable insights into their future growth trajectories.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Research and Development Investment: Pharming Group N.V. vs Amicus Therapeutics, Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: ADMA Biologics, Inc. vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
R&D Spending Showdown: ACADIA Pharmaceuticals Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Research and Development Investment: Amicus Therapeutics, Inc. vs Viridian Therapeutics, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.